Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 11/20 | 0.45 |
| ▸ | TNKS | O95271 | 10/20 | 0.45 |
| ▸ | WNT3A | P56704 | 6/20 | 0.45 |
| ▸ | PARP1 | P09874 | 6/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 0.41 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.40 |
| ▸ | AXIN2 | Q9Y2T1 | 1/20 | 0.40 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.40 |
| ▸ | TYMP | P19971 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31422809 | 0.65 | COMT (0.54) | COMTTNKS2TNKSWNT3APARP1 | |
| SCHEMBL15693144 | 0.64 | TNKS2 (0.56) | COMTTNKS2TNKSWNT3APARP1 | |
| SCHEMBL2433653 | 0.64 | COMT (1.00) | COMTTNKS2TNKSWNT3APARP1 | |
| SCHEMBL11622428 | 0.64 | KDM4E (0.50) | — | |
| SCHEMBL15693143 | 0.64 | TNKS2 (0.60) | COMTTNKS2TNKSWNT3APARP1 | |
| SCHEMBL10316101 | 0.63 | COMT (0.44) | COMTTNKS2TNKSWNT3APARP1 | |
| SCHEMBL15693156 | 0.62 | TNKS2 (0.54) | COMTTNKS2TNKSWNT3APARP1 | |
| SCHEMBL11284110 | 0.62 | TNKS (1.00) | TNKS2TNKSWNT3APARP1PARP2 | |
| SCHEMBL5833712 | 0.62 | COMT (0.65) | COMTTNKS2TNKSWNT3APARP1 | |
| SCHEMBL15527656 | 0.61 | TNKS (0.46) | TNKS2TNKSWNT3APARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2229392-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE AS GSK3BETA INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2009-10-15 | — | — | US | disclosed |
| WO-2009074259-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009074259-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258877-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THEIR USE | THPO, IL5, TPMT | COMT 1517/4885TNKS2 50/4885TNKS 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.